Smad4 is critical for self-renewal of hematopoietic stem cells by Karlsson, Göran et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
BRIEF DEFINITIVE REPORT
JEM © The Rockefeller University Press  $15.00
Vol. 204, No. 3,  March 19, 2007  467–474  www.jem.org/cgi/doi/10.1084/jem.20060465
467
On the cell surface, TGF-β superfamily growth 
factors, including TGF-βs, activins, and bone 
morphogenetic proteins (BMPs), bind to type I 
and type II serine/threonine kinase receptors. 
Upon association with the ligand, type II re-
ceptors form a complex with their respective 
type I receptors. Subsequently, TGF-β and ac-
tivin signals progress through phosphorylation 
of receptor-activated Smads (R-Smads) 2 and 3, 
whereas R-Smads 1, 5, and 8 mediate BMP 
signaling. R-Smads of both pathways eventu-
ally heteroligomerize with the common 
  mediator Smad4, and the resulting complex 
translocates to the nucleus and recruits tran-
scriptional cofactors to control gene expression. 
Additionally, in a negative feedback mecha-
nism, Smad6 and 7 inhibit TGF-β superfamily 
signaling by competing with R-Smads for 
Smad4 interaction and receptor binding and by 
targeting receptors for ubiquitination and deg-
radation. In addition to the canonical Smad 
circuitry, TGF-β superfamily members have 
been reported to signal through other path-
ways, predominantly including members of 
the mitogen-activated protein kinase (MAPK) 
family (1).
In the hematopoietic system, numerous
TGF-β family members have been established as 
modulators of hematopoietic stem cell (HSC) 
fate decisions (2–4). BMP-4 is critical for meso-
derm formation and, thus, hematopoietic devel-
opment in various model organisms, as well as 
from human embryonic stem cells. Further-
more, BMP stimulation aff  ects proliferation and 
diff  erentiation of human hematopoietic progen-
itors and can prolong the maintenance of func-
tional human cord blood HSCs in vitro through 
as of yet unidentifi  ed mechanisms. Conversely, 
the TGF-βs are generally context-dependent, 
potent inhibitors of primitive hematopoietic cell 
proliferation in vitro. The mechanisms behind 
TGF-β–induced growth arrest in hematopoietic 
progenitors are intricate, involving both down-
regulation of cytokine receptors and modulation 
of genes involved in the cell cycle. Previously, it 
has been reported that TGF-β1–null mice and 
inducible TGF-β receptor (TβR) knockout 
models develop a transplantable lethal infl  am-
matory disorder aff  ecting multiple organs (5–7). 
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However, transplantation experiments using BM from 
TβRI−/− mice failed to reveal any eff  ect on HSC proliferation 
and diff  erentiation in vivo, even though TβRI-defi  cient 
primitive hematopoietic cells had increased proliferative capac-
ity in vitro under low stimulatory conditions (8). Redundant 
mechanisms within the Smad signaling network or cross talk 
with other pathways relevant in the more complex and endur-
ing in vivo setting may account for this discrepancy between 
in vitro and in vivo fi  ndings. Indeed, members of the Wnt-, 
Notch-, and MAPK-signaling pathways have been suggested to 
interact with the Smads in other contexts (9–11). Recent work 
identifi  es the nuclear protein transcription intermediary factor 1 
(TIF1) γ as a competitor to Smad4 for R-Smad binding in hu-
man CD34+ cells, demonstrating additional complexities in the 
interaction between the canonical Smad pathway and other 
regulatory circuits in hematopoietic cells (12).
In this paper, we have studied the complete role of 
Smad4-dependent signaling in HSCs and hematopoiesis 
by means of inducible MxCre/Smad4−/− mice. Previously, 
several groups demonstrated that conventional Smad4−/− 
embryos die at embryonic day 7.5 because of an impaired 
proliferation of the ectoderm, resulting in a lack of mesoderm 
formation (13, 14). Adult Smad4 heterozygote mice develop 
polyps and tumors of the gastrointestinal tract (15, 16), fi  nd-
ings that have also been observed in human patients with ju-
venile polyposis syndrome caused by SMAD4 mutations (17). 
Correspondingly, we observed that MxCre-induced dele-
tion of Smad4 in hematopoietic and extrahematopoietic 
tissues results in histopathological changes in the colonic mu-
cosa and intestinal bleeding, reinforcing the importance of 
Smad signaling in colon homeostasis. By using cells from 
these mice in BM transplantation settings, we have isolated 
Figure 1.  Induction of Smad4 defi  ciency leads to death caused by 
a gastrointestinal disorder. (a) Animal weight change after Smad4 
  deletion. Results are shown as the mean ± SEM from two independent 
experiments (WT, n = 4; Smad4−/−, n = 9). (b) Animal weight change after 
gene deletion in Smad4−/− mice with WT BM and control mice. Results 
are shown as the mean ± SEM of one experiment (n = 3 for both 
  genotypes). (c and d) Pathological changes in the colon submucosa after 
Smad4 deletion. Bar, 100 μm. Lu, lumen; crypt, crypts of Lieberkuhns. 
(e) RBC counts for Smad4−/− and BMT-KO mice. Results are shown as the 
mean ± SEM (WT, n = 4; Smad4−/−, n = 4; BMT-KO, n = 3).JEM VOL. 204, March 19, 2007  469
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hematopoietic-intrinsic and extrahematopoietic defects asso-
ciated with Smad4 defi  ciency. Importantly, we reveal a novel 
role for Smad4-dependent signaling as a cell-autonomous 
critical regulator of HSC self-renewal in vivo.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
Induced Smad4 deletion is lethal in a manner distinct 
from the infl  ammatory phenotype of upstream TGF-𝗃 
signaling knockouts
In addition to the MxCre-induced gene deletion being essen-
tially 100% effi   cient in the BM, the Mx1 promoter is active in 
numerous other tissues (18). Hence, we created two experi-
mental models: one in which steady-state WT or transgenic 
MxCre/Smad4fl / fl  were induced (hereafter referred to as 
Smad4−/− or Smad4 defi  cient), and another in which lethally 
irradiated Smad4fl  /fl   mice were transplanted with WT BM be-
fore induction (BMT-KOs), eff  ectively isolating Smad4 dele-
tion to tissues outside the BM. Subsequent to gene deletion, 
the two models were monitored for weight gain as an indica-
tor of health. Approximately 3 wk after induction, Smad4-
  defi  cient mice began to lose weight and most were moribund 
4 wk after induction (Fig. 1 a). The BMT-KOs remained healthy 
for up to 7 wk after induction, as measured by weight gain, 
after which they slowly started to lose weight compared with 
WT controls (Fig. 1 b). Histopathological examination of the 
liver, kidney, heart, lungs, esophagus, pancreas, and small intes-
tines of Smad4−/− mice did not reveal evidence of tissue 
damage or infl  ammatory infi  ltration, as has been previously 
reported in models defi  cient in TGF-β signaling (unpublished 
data) (5–7). However, all Smad4−/− animals examined (n = 6) 
demonstrated apparent pathological changes in the colonic 
mucosa (Fig. 1 d), characterized by dilated glands and an en-
larged lamina propria surrounding the crypts of Lieberkuhns. 
Furthermore, the crypts were increased in size but reduced 
in number and were infi  ltrated with macrophages. This fi  nd-
ing had similarities with the phenotype seen in the small 
intestines of inducible MxCre/Bmpr1a-defi  cient mice (19). 
Surprisingly, colon histology of BMT-KO mice was normal 
10 wk after induction (unpublished data), suggesting a mech-
anistic link between Smad4 deletion in the BM with the co-
lon phenotype of Smad4−/− mice. This result is especially 
intriguing in light of recent fi  ndings by Kim et al., demon-
strating a requirement for Smad4 in T cells in the mainte-
nance of colon homeostasis (20).
Peripheral blood (PB) cell counts revealed a substantial 
reduction in RBCs (Fig. 1 e) and hemoglobin levels (not de-
picted) in Smad4−/− mice, whereas myeloid and lymphoid 
lineage distributions were normal (not depicted). Similarly, 
PB analysis revealed that BMT-KOs were also anemic, sug-
gesting that Smad4−/− BM-derived cells are not required to 
generate this particular phenotype (Fig. 1 e). Feces from 
Smad4−/− and BMT-KO mice stained positive for hemo-
globin 3 wk after gene deletion (unpublished data), suggest-
ing that Smad4 deletion in the colon resulted in intestinal 
hemorrhage. Interestingly, these symptoms are paralleled in 
patients suff  ering from juvenile polyposis syndrome (17).
Smad4−/− HSCs possess normal differentiation capacity 
but impaired BM reconstitution
To determine the eff  ect of Smad4 defi  ciency on hemato-
poietic potential, we performed in vitro assays and BM transplan-
tations. Colony and single-cell proliferation assays demonstrated 
that clonogenicity and proliferation of hematopoietic pro-
genitors in vitro were unaff   ected by Smad4 defi  ciency 
  despite the insensitivity of Smad4−/− cells to TGF-β1 (Fig. S1, 
a–d, available at http://www.jem.org/cgi/content/full/
jem.20060465/DC1). Furthermore, Smad4−/− hematopoietic 
progenitors had normal homing potential (Fig. S2, a and b), 
and recipients transplanted with Smad4−/− BM were healthy 
and displayed normal PB cell counts and lineage distribution 
over the 16 wk they were monitored, suggesting that Smad4 
is dispensable for the diff  erentiation capacity of HSCs (Fig. 2, 
a and b). Intriguingly, we did not observe any anemia nor 
changes in the colon of recipients engrafted with Smad4−/− 
BM, suggesting that Smad4 deletion in both hematopoietic 
and colon cells is required for the observed disruption of 
  homeostasis of the colon submucosa in Smad4−/− steady-state 
mice. Earlier studies of TGF-β–null and inducible TβR-defi  -
cient mice resulted in a lethal multifocal infl  ammatory dis-
order in primary mice and recipients of BM transplantations 
(5–7). Although this phenotype was mediated by T cells 
(6, 21), the signaling mechanisms of the disease remain unknown. 
Importantly, recipients of Smad4−/− donor BM showed no 
signs of this infl  ammatory disease, suggesting that TGF-β–
regulated T cell homeostasis is mediated through Smad-
  independent mechanisms. This conclusion is supported by a 
previous study in which Smad signaling was repressed through 
overexpression of the inhibitory Smad7 in HSCs without 
any observed infl  ammatory phenotype (22). Collectively, we 
conclude that canonical Smad signaling is dispensable for the 
infl  ammatory phenotype earlier observed in transgenic mice 
with upstream disruptions of the TGF-β pathway. Instead, 
loss of Smad4 in both the hematopoietic system and in the 
colon leads to death of the mice because of a gastrointestinal 
disorder and intestinal hemorrhage with subsequent anemia.
Intriguingly, FACS analysis of long-term reconstituted re-
cipients revealed a slight but signifi  cant decrease in Smad4−/− 
donor engraftment in the BM as compared with recipients of 
WT donor cells (89.32 ± 1.6% vs. 94.6 ± 1.5%, respectively; 
P < 0.03), with a corresponding increase of the endogenous 
Ly5.1+ fraction (Fig. 2 c).
To confi  rm that the reconstituting HSCs and progenitors 
were truly Smad4−/−, we performed PCR analysis of CFU-
GM colonies from recipient BM 16 wk after receiving BM 
transplants from six diff  erent Smad4−/− donors (Fig. 2 d). 
Out of the 60 colonies analyzed, all were positive either for 
the null or the endogenous WT allele, whereas none were 
positive for fl   oxed alleles, demonstrating highly effi   cient 
MxCre-induced deletion of the Smad4 gene. Moreover, FACS 
analysis revealed that even though Smad4−/− donor and re-
cipient mice had normal fractions and absolute numbers of 
total HSC-enriched Lin− Sca1+ cKit+ (LSK) cells as com-
pared with controls (unpublished data), the proportion of 470  SMAD4 DEFICIENCY IN HEMATOPOIETIC STEM CELLS | Karlsson et al. 
donor-derived LSK cells was decreased in recipients receiv-
ing Smad4-defi   cient BM compared with those receiving 
WT BM (82.7 ± 0.2% vs. 96.7 ± 0.05%, respectively; Fig. 2, 
e and f). We followed this cell population through serial 
transplantations, passaging 2 × 106 BM cells to new lethally 
irradiated recipients. Intriguingly, FACS analysis of second-
ary recipients demonstrated that Smad4−/− donor LSK cells 
were more quickly outcompeted by endogenous HSCs than 
were WT LSK cells (Fig. 2 f), thus indicating HSC self-
  renewal defects. Importantly, these analyses confi  rmed that 
Smad4−/− HSCs were capable of reconstituting the hemato-
poietic system but suggested that they were compromised in 
their ability to do so.
Smad4−/− HSCs have impaired self-renewal
We further challenged the repopulative capacity of Smad4−/− 
cells using competitive assays. 2 × 105 Smad4−/− or WT BM 
cells were transplanted into lethally irradiated recipients 
  together with an equal number of normal competitor cells. 
In agreement with the impaired reconstitution capacity in 
noncompetitive assays, PB from recipients of Smad4−/− BM 
analyzed 4 wk after transplantation had a 2.5-fold lower 
hematopoietic reconstitution as compared with recipients re-
ceiving WT BM (15.1 ± 3.72% vs. 34.8 ± 4.8%, respectively; 
P < 0.02). Moreover, the contribution of Smad4−/− PB cells 
slightly decreased over time, reaching a level of 11.4 ± 3.5% 
at 16 wk after BM transplantation, as opposed to WT donor 
cells, which displayed a stable PB distribution over time (40.2 ± 
8%; P < 0.01; Fig. 3, a and b). Lineage distribution of the 
remaining Smad4−/− BM was normal at all time points after 
transplantation up to and  including 16 wk (Fig. 3 c). Strik-
ingly, Smad4−/− cells demonstrated a 40-fold reduction in 
engraftment compared with WT controls upon secondary 
transplantation (Fig. 3 d).
Furthermore, competitive repopulation units (CRUs) were 
quantifi  ed by transplanting limiting doses of Smad4-defi  cient 
or WT donor cells in competition with a set number (2 × 105) 
of normal cells to lethally irradiated recipients. The CRU 
Figure 2.  Smad4-defi  cient HSCs exhibit impaired repopulation 
capacity. (a) Hematopoietic cell counts and (b) lineage distribution. 
(c) Reconstitution of the hematopoietic system as measured by FACS 
analysis of engrafted Ly5.2+ donor cells in recipient BM after transplantation. 
Results shown are the mean ± SEM of three independent experiments (n = 8 
donors per genotype and 2–6 recipients per donor). *, P < 0.03 as measured 
by the Student’s t test. WBC, white blood cell. (d) A representative fi  gure of 
PCR analysis on CFU-GM colonies from BM 16 wk after transplantation. 
(e) FACS analysis showing the fraction of endogenous cells (Ly5.1+) in the LSK 
population in irradiated recipients after two noncompetitive transplanta-
tions. (f) Smad4−/− donor LSK cells (Ly 5.2+) are more quickly outcompeted 
by remaining endogenous cells during noncompetitive serial BM trans-
plantations. Results shown are the means ± SEM using two donors per 
genotype and six recipients per donor. Shaded bars, WT; open bars, Smad4−/−.JEM VOL. 204, March 19, 2007  471
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frequency in the Smad4−/− mice was estimated to be threefold 
lower as compared with control BM (Fig. 3 e), further support-
ing the fi  ndings of impaired reconstitution capacity and reduced 
numbers of phenotypically defi  ned HSCs/progenitors.
Notably, FACS analyses of HSC-enriched populations 
demonstrated that cell-cycle status and apoptosis were un-
aff   ected by Smad4 defi   ciency (Fig. S3, a–d, available at 
http://www.jem.org/cgi/content/full/jem.20060465/DC1). 
However, in response to myeolablative stress in vivo, Smad4−/− 
cells had a slight but signifi  cant decrease in proliferative capac-
ity compared with controls (Fig. S3, e and f), suggesting that 
their capacity to proliferate may not be as robust as that of WT 
cells at times of acute demand for a replenished blood system.
To ask whether the Smad4−/− phenotype was cell autono-
mous or dependent on the lack of Smad4 in the HSC niche, 
2 × 106 uninduced Smad4fl / fl  or WT BM cells were trans-
planted to lethally irradiated mice. 10 wk after transplantation, 
Smad4 deletion was induced, producing  chimeras with 
Smad4−/− or WT HSCs in a normal HSC niche. Competitive 
transplantation experiments using BM cells harvested from 
these mice yielded an analogous phenotype as when perform-
ing competitive transplantation assays using Smad4−/− donors 
averaging  50% of the reconstitution levels of WT cells 7 wk 
after transplantation (Fig. 3 f). Collectively, these experiments 
reveal a profound cell-autonomous defect in competitive 
repopulating capacity and self-renewal of Smad4−/− HSCs.
Figure 3.  Smad4−/− HSCs have a pronounced disadvantage in 
competitive transplantation settings. (a) Representative Ly5.1/Ly5.2 
FACS analysis of PB. Numbers indicate the percentage of cells in each 
quadrant. (b) Pooled data from two independent competitive trans-
plantation experiments at 16 wk after BM transplantation. Results 
shown are the mean percentage of PB ± SEM (n = 6 donors and 
2–3 recipients per donor for each genotype). (c) BM lineage distribu-
tion of Smad4−/− Ly5.2-reconstituting donor cells after 16 wk of 
competitive transplantation. (d) Donor contribution to PB 16 wk after 
secondary transplantations (n = 5 donors and 3 recipients per donor). 
(e) Limiting dilution assay and CRU numbers in Smad4−/− BM. The fi  g-
ure is based on four doses per donor, one WT and two Smad4−/−, and 
three to four recipients per donor. CRU numbers are presented as the 
mean ± SE. Squares and dashed line, Smad4−/−; diamonds and con-
tinuous line, WT. (f) Donor contribution 7 wk after competitive trans-
plantation using WT chimeras with Smad4−/− BM as donors. Results 
shown are the mean percentage of PB ± SEM (n = 4 donors and 3 
recipients per donor for each genotype; P < 0.02). Shaded bars, WT; 
open bars, Smad4−/−. *, P < 0.02; and **, P < 0.01 as measured by the 
Mann-Whitney test.472  SMAD4 DEFICIENCY IN HEMATOPOIETIC STEM CELLS | Karlsson et al. 
Molecular profi  ling of Smad4−/− LSK cells reveals 
down-regulation of Notch1 and c-myc
To gain insight into the eff  ect of Smad4 deletion on HSC 
function, we performed gene expression profi  ling  using 
quantitative real-time PCR. LSK cells defi  cient in Smad4 
display reduced expression of the transcription factor and 
cell-cycle regulator c-myc, which was down-regulated 1.6-
fold (P = 0.02; Table I). A recent loss-of-function study 
manifested a dual role for c-myc in mouse HSC function. 
MxCre-induced c-myc defi  ciency resulted in an expected de-
crease in proliferation of hematopoietic progenitors but also 
in an increase in HSC self-renewal, presumably because of 
defective migration out of the HSC niche (23). However, 
earlier work by Satoh et al. demonstrated that ectopic expres-
sion of c-myc–induced self-renewal of HSCs in vitro (24). 
In the same study, c-myc was shown to be transcriptionally in-
duced by Notch signaling. Correspondingly, we also observed 
a signifi  cant transcriptional down-regulation of the Notch1 
  receptor in Smad4-defi  cient hematopoietic populations en-
riched for HSCs (Table I). The Notch ligand Jagged1 is ex-
pressed on osteoblasts in the HSC niche in the BM and has 
been demonstrated to be an important regulator of HSC self-
renewal in vivo (25, 26). The down-regulation of Notch1 
would therefore be consistent with our observation of re-
duced self-renewal in vivo but unchanged in vitro prolifera-
tion of HSC-enriched populations.
Smad4 critically regulates adult HSC fate through the 
canonical Smad pathway and non-Smad regulatory circuits
In this paper, we demonstrate that Smad4 is critical for the 
regulation of HSC self-renewal in vivo without aff  ecting the 
ratio of the diff  erent hematopoietic lineages. Furthermore, it 
appears that the Smad4−/− HSC phenotype is cell autono-
mous but dependent on extrinsic signaling from the in vivo 
microenvironment, because in vitro proliferation was normal 
in Smad4−/− HSCs. Thus, our data suggest a positive role 
for Smad4 in HSCs in contrast to the documented growth-
  arresting eff  ect generated by the upstream TGF-β ligand. It is 
unlikely that this stimulatory eff  ect is caused by the weak 
HSC growth-promoting signals documented for BMP4 on 
human cells in vitro, as BMP4 does not seem to have analo-
gous eff  ects in mouse BM (27). In fact, recent work supports 
a negative role for Smad signaling on the whole in HSC self-
renewal, as interference of the pathway through oncoretro-
viral overexpression of the inhibitory Smad7 resulted in an 
in vivo expansion of HSCs (22). This, together with the ob-
servations presented here, suggest a model for Smad signaling 
in the regulation of HSC self-renewal, where the positive 
role of Smad4 is caused by mechanisms outside the canonical 
Smad signaling pathway (Fig. 4). This idea is supported by 
the observation that in vivo expansion of Smad7-over-
expressing HSCs is dependent on Smad4 (22).
An intriguing recent report demonstrates a previously un-
known alternative pathway for TGF-β signaling in which TIF1γ 
competes with Smad4 to form complexes with Smad2 and 3. 
Figure 4.  Model for the regulation of HSC self-renewal by the 
Smad signaling pathway. The canonical Smad pathway inhibits HSC 
expansion. This inhibition can be relieved upon enforced expression of 
the inhibitory Smad7. Recently, TIF1γ has been shown to compete with 
Smad4 for binding of R-Smads, leading to differentiation of primitive 
cells into erythrocytes. In addition to its inhibitory role in HSCs as a criti-
cal partner in the canonical Smad pathway, Smad4 has a positive effect 
on self-renewal, possibly as a transducer of unknown regulators outside 
this pathway.
Table I.  Gene expression analysis of LSK cells
Gene (number of mice 
per genotype)
Fold change 
(KO/WT)
Cell-cycle regulators p15 (n = 2) nd
p18 (n = 2) −1.17 ± 0.04
p21 (n = 4) 1.11 ± 0.4
p27 (n = 4) 1.02 ± 0.23
p57 (n = 1) nd
Id1 (n = 4) nd
Id2 (n = 2) 1.25 ± 0.33
Id3 (n = 2) nd
c-myc (n = 5) −1.6 ± 0.14**
Transcription regulators Gata2 (n = 4) −1.31 ± 0.18
Hoxb4 (n = 4) 1.19 ± 0.93
Bmi1 (n = 3) 1.22 ± 0.1
Gfi  1 (n = 4) −1.19 ± 0.42
C/EBPa (n = 4) 1.3 ± 1.1
Receptors Fzd1 (n = 2) nd
c-kit (n = 2) 1.22 ± 0.13
c-mpl (n = 2) −1.23 ± 0.04
Notch1 (n = 5) −1.78 ± 0.18*
Signaling molecules Lnk (n = 2) −1.12 ± 0.11
Spry2 (n = 2) −1.26 ± 0.18
Results show the average fold difference in expression ± SEM. **, P = 0.02; and 
*, P = 0.03 as measured by paired t test. nd, not detectable.JEM VOL. 204, March 19, 2007  473
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In an apparent balancing act, TGF-β–induced R-Smad–Smad4 
complexes keep hematopoietic progenitors quiescent, whereas 
R-Smad–TIF1γ complexes direct human primitive hemato-
poietic cells toward erythroid diff  erentiation (12). Our data would 
support a model in which the absence of Smad4 tips the balance 
in favor of diff  erentiation at the expense of self-renewing divi-
sions. Additionally, emerging data suggest that other intracellular 
pathways directly aff  ect Smad signal transduction. Such cross talk 
is well established between MAPK and Smad pathways, where it 
has been shown that the linker region of Smads can serve as a 
phosphorylation site for MAPKs, ultimately inhibiting Smad 
translocation to the nucleus (9). Furthermore, it has been dem-
onstrated that β-catenin and Lef1/TCF, which are downstream 
mediators of the Wnt signaling cascade, can form a functional 
complex with Smad4 (11). Moreover, Notch and TGF-β signal-
ing have been demonstrated to converge at the regulation of 
Hes1 expression (10). These fi  ndings are important in this con-
text, because Wnt and Notch signaling stimulate proliferation of 
HSCs (25, 26, 28, 29). In summary, we demonstrate that Smad4 
is a critical regulator of HSC self-renewal in vivo without aff  ect-
ing lineage choice. Therefore, signaling pathways and other HSC 
regulators that require Smad4 to mediate their eff  ects will be 
important topics for future studies of HSC function.
MATERIALS AND METHODS
Mice. Mice with a mixed 129/FVB/Black Swiss background carrying loxP 
sites fl  anking one allele of exon 8 of the Smad4 locus (Smad4fl / +) (30) were 
mated to homozygosity and subsequently crossed with MxCre-transgenic 
C57BL/6 mice to generate conditional MxCre/Smad4fl  /fl  knockout mice. 
Poly I:C–induced deletion of the fl  oxed exon was induced in 7–12-wk-old 
mice, unless other stated, as previously described (8). All animal experiments 
were approved by the Lund University Animal Ethical Committee.
Histology. 5-wk-old MxCre/Smad4fl / fl  and WT control mice (MxCre/
Smad4+/+ or Cre− Smad4fl / fl ) were killed 28–32 d after the last poly I:C 
injection, and organs were embedded after fi  xation in PBS containing 4% 
paraformaldehyde. Bones were incubated in Parengy decalcifi  cation solution 
(0.15% chromethrioxid, 4.3% nitric acid, and 30% ethanol; Bie & Berntsen 
AS) for 48 h. Organs were subsequently sectioned and stained with Erlish 
eosin for microscopic examination.
BM transplantation assays. BM was harvested from 7–12-wk-old 
MxCre/Smad4fl / fl  and littermate control mice (Ly5.2) killed 7–10 d after the 
last poly I:C injection, and 2 × 106 BM cells were transplanted into the 
tail vein of lethally irradiated (9 cGy) C57BL/6 × B6SJL recipient mice 
(Ly5.1/Ly5.2). In the case of serial BM transplantations, 2 × 106 BM cells 
were passaged into new lethally irradiated recipients 8 wk after transplant.
In the competitive repopulation assay, 2 × 105 Smad4−/− or littermate 
control (WT) donor cells were transplanted into lethally irradiated Ly5.1/Ly5.2 
recipients together with 2 × 105 competitor cells from B6SJL (Ly5.1) mice.
In the case of competitive transplantation from the Smad4fl / fl /WT chi-
meras, 2 × 106 BM cells from uninduced MxCre/Smad4fl / fl  were transplanted 
into WT C57BL/6 × B6SJL mice. 10 wk after transplantation, the mice 
were induced, and competitive transplantation was performed as described 
earlier in this section.
CRU assay was performed using four cell doses ranging between 5 × 
103 and 105 BM cells per donor genotype, together with 2 × 105 normal 
competitor cells. PB was analyzed 12 wk after transplantation, and a cell dose 
was considered to contain at least one CRU if donor chimerism was >1% 
for both the myeloid and lymphoid lineages. The CRU frequency was 
  calculated on the basis of negative recipients using L-calc software (StemCell 
Technologies Inc.).
FACS analyses. The following fl  uorochrome-conjugated antibodies were 
purchased from BD Biosciences: anti-B220, -CD3, -Gr1, -Mac1, -CD45.1, 
-CD45.2, -CD4, -CD8, -Ter119, -CD71, -Sca1, -Kit, and -CD34. Lineage-
positive cells were labeled with unconjugated antibodies and Tri-color–
c  onjugated goat F(ab′)2 anti–rat immunoglobulin G as a secondary antibody.
Quantitative RT-PCR. Gene-specifi  c primers (Applied Biosystems) were 
used to analyze the expression of 20 genes of interest (Table I), together 
with the housekeeping gene hypoxanthine guanine phosphoribosyl trans-
ferase (Hprt).
Online supplemental material. Fig. S1 shows that Smad4−/− hemato-
poietic progenitors have normal in vitro proliferation and colony-forming 
capacity while being resistant to TGF-β–induced growth suppression. Fig. 
S2 demonstrates that Smad4 is dispensable for homing of hematopoietic pro-
genitors to the BM. Fig. S3 shows that Smad4−/− hematopoietic progenitors 
have normal apoptosis and cell-cycle status while having a reduced stress-
  induced proliferative capacity. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20060465/DC1.
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